Brookmont Capital Management Gilead Sciences, Inc. Transaction History

Brookmont Capital Management

$194 Million
Q3 2024

A detailed history of Brookmont Capital Management transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Brookmont Capital Management holds 43,761 shares of GILD stock, worth $4.13 Million. This represents 1.89% of its overall portfolio holdings.

Number of Shares

43,761

Previous 45,196 3.18%

Holding current value

$4.13 Million

Previous $3.1 Million 18.32%

% of portfolio

1.89%

Previous 1.7%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 16, 2024	SELL	$66.59 - $83.99 $95,556 - $120,525	-1,435 Reduced 3.18%	43,761 $3.67 Million
Q2 2024 Jul 17, 2024	SELL	$63.15 - $72.88 $93,967 - $108,445	-1,488 Reduced 3.19%	45,196 $3.1 Million
Q1 2024 Apr 16, 2024	BUY	$71.58 - $87.29 $71,937 - $87,726	1,005 Added 2.2%	46,684 $3.42 Million
Q4 2023 Jan 18, 2024	SELL	$73.27 - $83.09 $59,495 - $67,469	-812 Reduced 1.75%	45,679 $3.7 Million
Q3 2023 Oct 12, 2023	SELL	$73.94 - $80.67 $24,104 - $26,298	-326 Reduced 0.7%	46,491 $3.48 Million
Q2 2023 Jul 13, 2023	BUY	$76.01 - $86.7 $1,900 - $2,167	25 Added 0.05%	46,817 $3.61 Million
Q1 2023 Apr 11, 2023	BUY	$77.31 - $88.08 $16,389 - $18,672	212 Added 0.46%	46,792 $3.88 Million
Q4 2022 Feb 06, 2023	BUY	$62.32 - $89.47 $1.07 Million - $1.54 Million	17,238 Added 58.75%	46,580 $4 Million
Q3 2022 Oct 12, 2022	BUY	$59.54 - $68.01 $139,680 - $159,551	2,346 Added 8.69%	29,342 $1.81 Million
Q2 2022 Aug 15, 2022	BUY	$57.72 - $65.01 $20,259 - $22,818	351 Added 1.32%	26,996 $1.67 Million
Q1 2022 May 09, 2022	BUY	$57.92 - $72.58 $33,072 - $41,443	571 Added 2.19%	26,645 $1.58 Million
Q4 2021 Jan 27, 2022	SELL	$64.88 - $73.64 $71,627 - $81,298	-1,104 Reduced 4.06%	26,074 $1.89 Million
Q3 2021 Nov 15, 2021	BUY	$67.69 - $73.03 $34,792 - $37,537	514 Added 1.93%	27,178 $1.9 Million
Q2 2021 Jul 19, 2021	BUY	$63.47 - $69.35 $1,142 - $1,248	18 Added 0.07%	26,664 $1.84 Million
Q1 2021 Apr 15, 2021	BUY	$60.0 - $68.46 $10,800 - $12,322	180 Added 0.68%	26,646 $1.72 Million
Q4 2020 Feb 04, 2021	SELL	$56.65 - $64.55 $94,605 - $107,798	-1,670 Reduced 5.94%	26,466 $1.54 Million
Q3 2020 Oct 16, 2020	BUY	$62.1 - $78.08 $32,167 - $40,445	518 Added 1.88%	28,136 $1.78 Million
Q2 2020 Jul 23, 2020	SELL	$72.34 - $84.0 $807,603 - $937,776	-11,164 Reduced 28.79%	27,618 $2.13 Million
Q1 2020 Apr 28, 2020	BUY	$62.63 - $80.22 $201,981 - $258,709	3,225 Added 9.07%	38,782 $2.9 Million
Q4 2019 Jan 22, 2020	SELL	$61.62 - $67.78 $181,162 - $199,273	-2,940 Reduced 7.64%	35,557 $2.31 Million
Q3 2019 Nov 07, 2019	SELL	$62.51 - $69.0 $7,813 - $8,625	-125 Reduced 0.32%	38,497 $2.44 Million
Q2 2019 Jul 18, 2019	BUY	$61.87 - $69.38 $12,064 - $13,529	195 Added 0.51%	38,622 $2.61 Million
Q1 2019 Apr 16, 2019	BUY	$62.53 - $70.05 $5,064 - $5,674	81 Added 0.21%	38,427 $2.5 Million
Q4 2018 Feb 12, 2019	BUY	$60.54 - $79.0 $27,303 - $35,629	451 Added 1.19%	38,346 $2.4 Million
Q3 2018 Nov 08, 2018	BUY	$71.28 - $78.92 $2,922 - $3,235	41 Added 0.11%	37,895 $2.93 Million
Q2 2018 Jul 19, 2018	BUY	$64.88 - $75.68 $280,735 - $327,467	4,327 Added 12.91%	37,854 $2.68 Million
Q1 2018 May 14, 2018	SELL	$72.84 - $88.8 $2.29 Million - $2.79 Million	-31,387 Reduced 48.35%	33,527 $2.53 Million
Q4 2017 Feb 12, 2018	BUY	$71.15 - $83.52 $1.54 Million - $1.81 Million	21,628 Added 49.97%	64,914 $4.65 Million
Q3 2017 Nov 13, 2017	BUY	$72.11 - $85.47 $3.12 Million - $3.7 Million	43,286	43,286 $3.51 Million

Others Institutions Holding GILD

# of Institutions

1,926

Shares Held

992M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $118B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Brookmont Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Brookmont Capital Management with notifications on news.

Account

Brookmont Capital Management Gilead Sciences, Inc. Transaction History